Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Goodwill (2022 - 2025)

Historic Goodwill for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $12.0 million.

  • Axsome Therapeutics' Goodwill changed 0.0% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $12.0 million for FY2024, which is 0.0% changed from last year.
  • Axsome Therapeutics' Goodwill amounted to $12.0 million in Q3 2025, which was down 0.0% from $12.0 million recorded in Q2 2025.
  • Axsome Therapeutics' Goodwill's 5-year high stood at $12.0 million during Q2 2023, with a 5-year trough of $10.3 million in Q4 2022.
  • Moreover, its 4-year median value for Goodwill was $12.0 million (2023), whereas its average is $11.8 million.
  • As far as peak fluctuations go, Axsome Therapeutics' Goodwill soared by 1679.92% in 2023, and later changed by 0.0% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Goodwill stood at $10.3 million in 2022, then grew by 16.8% to $12.0 million in 2023, then changed by 0.0% to $12.0 million in 2024, then changed by 0.0% to $12.0 million in 2025.
  • Its Goodwill was $12.0 million in Q3 2025, compared to $12.0 million in Q2 2025 and $12.0 million in Q1 2025.